Afficher la notice abrégée

Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients

dc.rights.licenseopenen_US
dc.contributor.authorOLEARO, F.
dc.contributor.authorNGUYEN, H.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBONNET, Fabrice
dc.contributor.authorYERLY, S.
dc.contributor.authorWANDELER, G.
dc.contributor.authorSTOECKLE, M.
dc.contributor.authorCAVASSINI, M.
dc.contributor.authorSCHERRER, A.
dc.contributor.authorCOSTAGIOLA, D.
dc.contributor.authorSCHMID, P.
dc.contributor.authorGUNTHARD, H. F.
dc.contributor.authorBERNASCONI, E.
dc.contributor.authorBOENI, J.
dc.contributor.authorD'ARMINIO MONFORTE, A.
dc.contributor.authorZAZZI, M.
dc.contributor.authorROSSETTI, B.
dc.contributor.authorNEAU, D.
dc.contributor.authorBELLECAVE, P.
dc.contributor.authorRIJNDERS, B.
dc.contributor.authorREISS, P.
dc.contributor.authorWIT, F.
dc.contributor.authorKOUYOS, R.
dc.contributor.authorCALMY, A.
dc.date.accessioned2020-07-09T14:45:27Z
dc.date.available2020-07-09T14:45:27Z
dc.date.issued2019-10
dc.identifier.issn2328-8957 (Print) 2328-8957en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/10370
dc.description.abstractEnObjective: The impact of the M184V/I mutation on the virological failure (VF) rate in HIV-positive patients with suppressed viremia switching to an abacavir/lamivudine/dolutegravir regimen has been poorly evaluated. Method: This is an observational study from 5 European HIV cohorts among treatment-experienced adults with </=50 copies/mL of HIV-1 RNA who switched to abacavir/lamivudine/dolutegravir. Primary outcome was the time to first VF (2 consecutive HIV-1 RNA >50 copies/mL or single HIV-1 RNA >50 copies/mL accompanied by change in antiretroviral therapy [ART]). We also analyzed a composite outcome considering the presence of VF and/or virological blips. We report also the results of an inverse probability weighting analysis on a restricted population with a prior history of VF on any ART regimen to calculate statistics standardized to the disparate sampling population. Results: We included 1626 patients (median follow-up, 288.5 days; interquartile range, 154-441). Patients with a genotypically documented M184V/I mutation (n = 137) had a lower CD4 nadir and a longer history of antiviral treatment. The incidence of VF was 29.8 cases (11.2-79.4) per 1000 person-years in those with a previously documented M184V/I, and 13.6 cases (8.4-21.8) in patients without documented M184V/I. Propensity score weighting in a restricted population (n = 580) showed that M184V/I was not associated with VF or the composite endpoint (hazard ratio [HR], 1.27; 95% confidence interval [CI], 0.35-4.59 and HR 1.66; 95% CI, 0.81-3.43, respectively). Conclusions: In ART-experienced patients switching to an abacavir/lamivudine/dolutegravir treatment, we observed few VFs and found no evidence for an impact of previously-acquired M184V/I mutation on this outcome. Additional analyses are required to demonstrate whether these findings will remain robust during a longer follow-up.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Unported
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/3.0/
dc.subject.enMORPH3Eus
dc.title.enImpact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients
dc.title.alternativeOpen Forum Infect Disen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/ofid/ofz330en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed31660328en_US
bordeaux.journalOpen forum infectious diseasesen_US
bordeaux.pageofz330en_US
bordeaux.volume6en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue10en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Open%20forum%20infectious%20diseases&amp;rft.date=2019-10&amp;rft.volume=6&amp;rft.issue=10&amp;rft.spage=ofz330&amp;rft.epage=ofz330&amp;rft.eissn=2328-8957%20(Print)%202328-8957&amp;rft.issn=2328-8957%20(Print)%202328-8957&amp;rft.au=OLEARO,%20F.&amp;NGUYEN,%20H.&amp;BONNET,%20Fabrice&amp;YERLY,%20S.&amp;WANDELER,%20G.&amp;rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_OFID_2019_Olearo.pdf
Taille:
592.4Ko
Format:
PDF
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée